Literature DB >> 25131989

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Ariel Halper-Stromberg1, Ching-Lan Lu2, Florian Klein1, Joshua A Horwitz1, Stylianos Bournazos3, Lilian Nogueira1, Thomas R Eisenreich1, Cassie Liu1, Anna Gazumyan1, Uwe Schaefer4, Rebecca C Furze5, Michael S Seaman6, Rab Prinjha5, Alexander Tarakhovsky4, Jeffrey V Ravetch3, Michel C Nussenzweig7.   

Abstract

Latent reservoirs of HIV-1-infected cells are refractory to antiretroviral therapies (ART) and remain the major barrier to curing HIV-1. Because latently infected cells are long-lived, immunologically invisible, and may undergo homeostatic proliferation, a "shock and kill" approach has been proposed to eradicate this reservoir by combining ART with inducers of viral transcription. However, all attempts to alter the HIV-1 reservoir in vivo have failed to date. Using humanized mice, we show that broadly neutralizing antibodies (bNAbs) can interfere with establishment of a silent reservoir by Fc-FcR-mediated mechanisms. In established infection, bNAbs or bNAbs plus single inducers are ineffective in preventing viral rebound. However, bNAbs plus a combination of inducers that act by independent mechanisms synergize to decrease the reservoir as measured by viral rebound. Thus, combinations of inducers and bNAbs constitute a therapeutic strategy that impacts the establishment and maintenance of the HIV-1 reservoir in humanized mice.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25131989      PMCID: PMC4163911          DOI: 10.1016/j.cell.2014.07.043

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  67 in total

Review 1.  Fcgamma receptors as regulators of immune responses.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

2.  A mouse model for HIV-1 entry.

Authors:  John Pietzsch; Henning Gruell; Stylianos Bournazos; Bridget M Donovan; Florian Klein; Ron Diskin; Michael S Seaman; Pamela J Bjorkman; Jeffrey V Ravetch; Alexander Ploss; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

3.  Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure.

Authors:  Amy W Chung; Gamze Isitman; Marjon Navis; Marit Kramski; Rob J Center; Stephen J Kent; Ivan Stratov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

4.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

5.  Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells.

Authors:  Kavita M Dhodapkar; Jacob L Kaufman; Marc Ehlers; Devi K Banerjee; Ezio Bonvini; Scott Koenig; Ralph M Steinman; Jeffrey V Ravetch; Madhav V Dhodapkar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-09       Impact factor: 11.205

6.  Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors:  C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

9.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

10.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection.

Authors:  M I Bukrinsky; T L Stanwick; M P Dempsey; M Stevenson
Journal:  Science       Date:  1991-10-18       Impact factor: 63.714

View more
  214 in total

1.  Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.

Authors:  Yijun Zhang; James H Chapman; Asim Ulcay; Richard E Sutton
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 2.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Authors:  Ariel Halper-Stromberg; Michel C Nussenzweig
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

3.  Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice.

Authors:  Anne-Sophie Kuhlmann; Kevin G Haworth; Isaac M Barber-Axthelm; Christina Ironside; Morgan A Giese; Christopher W Peterson; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2018-09-27       Impact factor: 11.454

Review 4.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

5.  In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.

Authors:  Kieran Seay; Candice Church; Jian Hua Zheng; Kathryn Deneroff; Christina Ochsenbauer; John C Kappes; Bai Liu; Emily K Jeng; Hing C Wong; Harris Goldstein
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

Review 6.  Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice.

Authors:  Lishan Su
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

7.  Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.

Authors:  Johannes Brozy; Erika Schlaepfer; Markus Muenz; Roberto F Speck; Christina K S Mueller; Mary-Aude Rochat; Silvana K Rampini; Renier Myburgh; Tobias Raum; Peter Kufer; Patrick A Baeuerle
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 8.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

9.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

10.  The Transcription Factor AP4 Mediates Resolution of Chronic Viral Infection through Amplification of Germinal Center B Cell Responses.

Authors:  Chun Chou; Daniel J Verbaro; Elena Tonc; Melanie Holmgren; Marina Cella; Marco Colonna; Deepta Bhattacharya; Takeshi Egawa
Journal:  Immunity       Date:  2016-08-23       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.